See the event website https://www.aacr.org/meeting/aacr-annual-meeting-2022/

Do not miss out poster presented April 12, 2022, 9:00 AM - 12:30 PM     Section 33 "CT188 / 13 - ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial"